, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE, Lee MT, Clinical Pharmacogenetics Implementation Consortium
Clin Pharmacol Ther. 2016 99 (1): 36-7

PMID: 26094938 · PMCID: PMC4675696 · DOI:10.1002/cpt.161

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

© 2015 American Society for Clinical Pharmacology and Therapeutics.

MeSH Terms (7)

Allopurinol Biomarkers, Pharmacological Drug Administration Schedule Genotype Guidelines as Topic HLA-B Antigens Humans

Connections (1)

This publication is referenced by other Labnodes entities: